Therapy Areas: Oncology
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights
29 October 2026 - Biotechnology company TME Pharma N.V. (Euronext Growth Paris:ALTME) said on Thursday that it has signed a binding exclusive negotiation agreement with Japanese clinical-stage biotech...
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
28 October 2026 - Computational chemistry company Evogene Ltd (NASDAQ: EVGN) (TASE: EVGN) announced on Wednesday that it has selected acute graft-versus-host disease (aGVHD) as the target indication f...
Genmab reports 50% reduction in risk of death in Phase 3 head and neck cancer trial
28 October 2026 - Danish biotechnology company Genmab A/S (CPH:GMAB) on Wednesday announced positive topline results from its Phase 3 LiGeR-HN1 trial, showing that petosemtamab combined with pembroliz...
Novocure and Verastem to evaluate combination therapy for pancreatic cancer
28 October 2026 - Global oncology company Novocure (Nasdaq:NVCR) said on Wednesday that it has entered into a clinical trial collaboration and supply agreement with biopharmaceutical company Verastem ...
US WorldMeds acquires Orbus Therapeutics
28 October 2026 - US-based specialty pharmaceutical company US WorldMeds Ventures LLC announced on Tuesday a definitive merger agreement under which it has acquired Orbus Therapeutics Inc, a privately...
Astellas and Audax Biosciences sign exclusive option and licence agreement for DAX-044
28 October 2026 - Japanese pharmaceutical company Astellas Pharma Inc (TSE:4503) and Australian biotechnology company Audax Biosciences Pty Ltd announced on Tuesday that they have entered into an excl...